Title:
BIOMARKER FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING EFFECT OF CANCER THERAPEUTIC DRUG ON CANCER PATIENT, AND KIT FOR PREDICTING PROGNOSIS OF CANCER PATIENT
Document Type and Number:
WIPO Patent Application WO/2023/002943
Kind Code:
A1
Abstract:
A biomarker for predicting the prognosis of a cancer patient, said biomarker comprising immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene; a method for predicting the prognosis of a cancer patient, said method comprising a step for measuring the expression level of immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene in a biological sample from the cancer patient; a method for predicting the effect of a substance, which inhibits the binding of fibronectin to immunosuppressive receptor LILRB4, as a cancer therapeutic drug on a cancer patient, said method comprising a step for measuring the expression level of immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene in a biological sample from the cancer patient; and a kit for predicting the prognosis of a cancer patient, said kit containing a reagent for measuring the expression level of the aforesaid biomarker.
Inventors:
TAKAI TOSHIYUKI (JP)
OKADA YOSHINORI (JP)
KUMATA SAKIKO (JP)
SU MEI TZU (JP)
ENDO SHOTA (JP)
NOTSUDA HIROTSUGU (JP)
TANAKA RYOTA (JP)
SAITO RYOKO (JP)
OKADA YOSHINORI (JP)
KUMATA SAKIKO (JP)
SU MEI TZU (JP)
ENDO SHOTA (JP)
NOTSUDA HIROTSUGU (JP)
TANAKA RYOTA (JP)
SAITO RYOKO (JP)
Application Number:
PCT/JP2022/027853
Publication Date:
January 26, 2023
Filing Date:
July 15, 2022
Export Citation:
Assignee:
UNIV TOHOKU (JP)
International Classes:
C12N15/11; C07K14/705; C12Q1/6851; C12Q1/686; G01N33/53; G01N33/574
Domestic Patent References:
| WO2021029318A1 | 2021-02-18 | |||
| WO2021029318A1 | 2021-02-18 |
Foreign References:
| CN112442535A | 2021-03-05 | |||
| CN111892661A | 2020-11-06 | |||
| CN112280862A | 2021-01-29 | |||
| JP2021119757A | 2021-08-19 | |||
| JP2018025554A | 2018-02-15 |
Other References:
DE GOEJE PAULINE L, BEZEMER KOEN, HEUVERS MARLIES E, DINGEMANS ANNE-MARIE C, GROEN HARRY JM, SMIT EGBERT F, HOOGSTEDEN HENK C, HEN: "Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer", ONCOIMMUNOLOGY, vol. 4, no. 7, 3 July 2015 (2015-07-03), pages e1014242, XP093026877, DOI: 10.1080/2162402X.2015.1014242
LI JUAN; GAO AIQIN; ZHANG FANG; WANG SHUYUN; WANG JINGNAN; WANG JING; HAN SHUYI; YANG ZIJIANG; CHEN XIAOZHENG; FANG YUYING; JIANG : "ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 501, 3 November 2020 (2020-11-03), US , pages 263 - 276, XP086469879, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2020.10.048
LIU JIE; LU CHUN-XIAO; ZHANG FANG; LV WEI; LIU CHUANYONG: "Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer", PATHOLOGY - RESEARCH AND PRACTICE, ELSEVIER, AMSTERDAM, NL, vol. 214, no. 10, 27 July 2018 (2018-07-27), AMSTERDAM, NL , pages 1621 - 1625, XP085482796, ISSN: 0344-0338, DOI: 10.1016/j.prp.2018.07.026
NATURE, vol. 562, no. 7728, October 2018 (2018-10-01), pages 605 - 609
HUM PATHOL, vol. 79, 2018, pages 188 - 198
J CLIN MED, vol. 24, no. 8, 2019, pages 743
ONCO TARGETS THER, vol. 9, no. 13, 2020, pages 215 - 224
"Hideaki Nagamune and Hiroshi Terada", 1990, HIROKAWA PUBLISHING COMPANY, article "Monoclonal Antibody"
JAME W. GOLDING: "Monoclonal Antibody", 1996, ACADEMIC PRESS
NATURE, vol. 356, 12 March 1992 (1992-03-12), pages 152 - 154
J. IMMUNOL METHODS MAR, vol. 1, no. 249, pages 147 - 154
Y SADO ET AL., ACTA HISTOCHEM. CYTOCHEM., vol. 39, 2006, pages 89 - 94
K HIRAYASU ET AL., NAT. MICROBIOL., vol. 1, 2016, pages 16054
LI JUAN; GAO AIQIN; ZHANG FANG; WANG SHUYUN; WANG JINGNAN; WANG JING; HAN SHUYI; YANG ZIJIANG; CHEN XIAOZHENG; FANG YUYING; JIANG : "ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 501, 3 November 2020 (2020-11-03), US , pages 263 - 276, XP086469879, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2020.10.048
LIU JIE; LU CHUN-XIAO; ZHANG FANG; LV WEI; LIU CHUANYONG: "Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer", PATHOLOGY - RESEARCH AND PRACTICE, ELSEVIER, AMSTERDAM, NL, vol. 214, no. 10, 27 July 2018 (2018-07-27), AMSTERDAM, NL , pages 1621 - 1625, XP085482796, ISSN: 0344-0338, DOI: 10.1016/j.prp.2018.07.026
NATURE, vol. 562, no. 7728, October 2018 (2018-10-01), pages 605 - 609
HUM PATHOL, vol. 79, 2018, pages 188 - 198
J CLIN MED, vol. 24, no. 8, 2019, pages 743
ONCO TARGETS THER, vol. 9, no. 13, 2020, pages 215 - 224
"Hideaki Nagamune and Hiroshi Terada", 1990, HIROKAWA PUBLISHING COMPANY, article "Monoclonal Antibody"
JAME W. GOLDING: "Monoclonal Antibody", 1996, ACADEMIC PRESS
NATURE, vol. 356, 12 March 1992 (1992-03-12), pages 152 - 154
J. IMMUNOL METHODS MAR, vol. 1, no. 249, pages 147 - 154
Y SADO ET AL., ACTA HISTOCHEM. CYTOCHEM., vol. 39, 2006, pages 89 - 94
K HIRAYASU ET AL., NAT. MICROBIOL., vol. 1, 2016, pages 16054
Attorney, Agent or Firm:
TAZAKI Akira et al. (JP)
Download PDF:
Previous Patent: LENS HOOD
Next Patent: ANTIBODY CAPABLE OF BINDING TO NOVEL CORONAVIRUS (SARS-COV-2) AND SARS CORONAVIRUS (SARS-COV)
Next Patent: ANTIBODY CAPABLE OF BINDING TO NOVEL CORONAVIRUS (SARS-COV-2) AND SARS CORONAVIRUS (SARS-COV)